课题组长：杨林
课题组主要从事靶向T 淋巴细胞的肿瘤免疫治疗新策略的转化医学研究，包括：嵌合体抗原受体基因修饰的T 淋巴细胞靶向治疗恶性肿瘤的研究、T 细胞/NK 细胞介导的双特异性肿瘤免疫治疗抗体药物研制、以及基于纳米抗体递送策略的靶向T 细胞免疫毒素药物的研究等。课题组成员荣获“江苏省高层次创新创业人才”、“江苏省六大人才高峰团队”等称号。
代表性成果 Representative Achievements：
论文
1. Meng H, Sun X, Song Y, Zou J, An G, Jin Z*, Yang*. La / SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease. Clin Immun 2018;192:40-9.
2. Zhao S, Han Z, Ji C, An G, Meng H, Yang L*. The research significance of concomitantuse of CAR-CD138-NK and CAR-CD19-NKto target multiple myelomas. European Journal of Inflammation 2018;16:1-9.
3. Zhang P, Zhao S, Wu C, Li J, Li Z, Wen C, Hu S, An G, Meng H, Zhang X, Yang L*. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI and T cells on tumor-associated macrophages. Immunotherapy 2018 Accepted.
4. Chen Y, You F, Jiang L,Li J, Zhu X, Bao Y, Sun X, Tang X, Meng H, An G, Zhang B, Yang L*. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody. Oncotarget 2017;8:37128-39.
5. Yu Y, Li J, Zhu X, Tang X, Bao Y, Sun X, Huang Y, Tian F, Liu X, Yang L*. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomedicine 2017;12:1969-83.
6. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J,HunzikerW, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L*, Orlowski RZ*. Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR/JAK1/STAT3 signaling. Cancer Cell 2016; 29:1-14.
7. You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, Wu H, Du K, Zhu Y, Meng H, Gong Z, Zong Y, Huang L, Lu M, Tang J, Li Y, Zhai X, Wang X, Ye S, Chen D, Yuan L, Qi L, Yang L*. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci 2016;59:386-97.
8. Zou J, Chen D, Zong Y, Ye S, Tang J, Meng H, An G, Zhang X, Yang L*. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. Cancer Sci 2015;106:512-21.